Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on June 23, 2003

Circulation. 2003
Published online before print June 23, 2003, doi: 10.1161/01.CIR.0000080735.93327.00
A more recent version of this article appeared on July 15, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/2/198    most recent
01.CIR.0000080735.93327.00v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sennlaub, F.
Right arrow Articles by Chemtob, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sennlaub, F.
Right arrow Articles by Chemtob, S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetic Eye Problems
Related Collections
Right arrow Angiogenesis
Right arrow Animal models of human disease
Right arrow Peripheral vascular disease
Right arrow Other diabetes
Right arrow Other Treatment
Right arrow Other Vascular biology

© American Heart Association, Inc.

Basic Science Reports

Cyclooxygenase-2 in Human and Experimental Ischemic Proliferative Retinopathy

F. Sennlaub, MD, PhD; F. Valamanesh, MSc; A. Vazquez-Tello, PhD; A. M. El-Asrar, MD, PhD; D. Checchin, MSc; S. Brault, MSc; F. Gobeil, PhD; M. H. Beauchamp, MSc; B. Mwaikambo, BSc; Y. Courtois, PhD; K. Geboes, MD, PhD; D. R. Varma, MD, PhD; P. Lachapelle, PhD; H. Ong, PhD; F. Behar-Cohen, MD, PhD S. Chemtob, MD, PhD

From the Departments of Pediatrics, Ophthalmology, and Pharmacology, Research Center of Hôpital Sainte-Justine (F.S., A.V.-T., D.C., S.B., F.G., M.H.B., B.M., S.C.); Departments of Pharmacology (D.R.V., B.M.) and Ophthalmology (P.L.), McGill University; and Faculty of Pharmacy, Université de Montréal (H.O.), Montreal, Québec, Canada, and Développement, Vieillissement et Pathologie de la Rétine, Institut National de la Santé et de la Recherche Médicale U450, Paris, France (F.V., Y.C., F.B.C.); Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia (A.M.E.-A.); and Department of Pathology, University Hospitals Leuven, Belgium (K.G.).

Correspondence to Florian Sennlaub, MD, PhD, Department of Pediatrics, Centre de Recherche, Hôpital Sainte-Justine, 3175, chemin de la Côte-Sainte-Catherine, Montréal, Québec, Canada H3T 1C5. E-mail fsennlaub{at}justine.umontreal.ca

Background— Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)–2 promotes tumor angiogenesis, we investigated the role of COX-2 in ischemic proliferative retinopathy.

Methods and Results— We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3 stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36.

Conclusion— These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes.


Key Words: prostaglandins • diabetes mellitus • ischemia • vasculature




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
B. R. Mwaikambo, C. Yang, S. Chemtob, and P. Hardy
Hypoxia Up-regulates CD36 Expression and Function via Hypoxia-inducible Factor-1- and Phosphatidylinositol 3-Kinase-dependent Mechanisms
J. Biol. Chem., September 25, 2009; 284(39): 26695 - 26707.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
Z. A. Radi
Pathophysiology of Cyclooxygenase Inhibition in Animal Models
Toxicol Pathol, January 1, 2009; 37(1): 34 - 46.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J.-A. C. Portillo, J. Van Grol, L. Zheng, G. Okenka, K. Gentil, A. Garland, E. C. Carlson, T. S. Kern, and C. S. Subauste
CD40 Mediates Retinal Inflammation and Neurovascular Degeneration
J. Immunol., December 15, 2008; 181(12): 8719 - 8726.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
K. Holmgaard, C. Aalkjaer, J. D. C. Lambert, and T. Bek
N-Methyl-D-Aspartic Acid Causes Relaxation of Porcine Retinal Arterioles through an Adenosine Receptor-Dependent Mechanism
Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4590 - 4594.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. S. Desai, M. M. Mariscalco, A. Tawil, J. G. Vallejo, and C. W. Smith
Atherogenic diet-induced hepatitis is partially dependent on murine TLR4
J. Leukoc. Biol., June 1, 2008; 83(6): 1336 - 1344.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
B. R. Mwaikambo, F. Sennlaub, H. Ong, S. Chemtob, and P. Hardy
Activation of CD36 Inhibits and Induces Regression of Inflammatory Corneal Neovascularization.
Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4356 - 4364.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
K. Wanggren, P.G. Lalitkumar, A. Stavreus-Evers, B. Stabi, and K. Gemzell-Danielsson
Prostaglandin E2 and F2{alpha} receptors in the human Fallopian tube before and after mifepristone treatment
Mol. Hum. Reprod., September 1, 2006; 12(9): 577 - 585.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Zhu, F. Sennlaub, M. H. Beauchamp, L. Fan, J. S. Joyal, D. Checchin, S. Nim, P. Lachapelle, M. Sirinyan, X. Hou, et al.
Proangiogenic Effects of Protease-Activated Receptor 2 Are Tumor Necrosis Factor-{alpha} and Consecutively Tie2 Dependent
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 744 - 750.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. C. Amrite, S. P. Ayalasomayajula, N. P. S. Cheruvu, and U. B. Kompella
Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage.
Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1149 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. N. Jabbour, R. W. Kelly, H. M. Fraser, and H. O. D. Critchley
Endocrine Regulation of Menstruation
Endocr. Rev., February 1, 2006; 27(1): 17 - 46.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. Pladys, F. Sennlaub, S. Brault, D. Checchin, I. Lahaie, N. L. O. Le, K. Bibeau, G. Cambonie, D. Abran, M. Brochu, et al.
Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1580 - R1588.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. S. Biswas, K. Banerjee, B. Kim, P. R. Kinchington, and B. T. Rouse
Role of Inflammatory Cytokine-Induced Cycloxygenase 2 in the Ocular Immunopathologic Disease Herpetic Stromal Keratitis
J. Virol., August 15, 2005; 79(16): 10589 - 10600.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
X. Zhang and A. H. Neufeld
Activation of the Epidermal Growth Factor Receptor in Optic Nerve Astrocytes Leads to Early and Transient Induction of Cyclooxygenase-2
Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 2035 - 2041.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. E. Walshe, G. Ferguson, P. Connell, C. O'Brien, and P. A. Cahill
Pulsatile Flow Increases the Expression of eNOS, ET-1, and Prostacyclin in a Novel In Vitro Coculture Model of the Retinal Vasculature
Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 375 - 382.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
D. S. Wall, R. L. Gendron, W. V. Good, E. Miskiewicz, M. Woodland, K. Leblanc, and H. Paradis
Conditional Knockdown of Tubedown-1 in Endothelial Cells Leads to Neovascular Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3704 - 3712.
[Abstract] [Full Text] [PDF]


Home page
Recent Prog Horm ResHome page
M. L. Wahl, T. L. Moser, and S. V. Pizzo
Angiostatin and Anti-angiogenic Therapy in Human Disease
Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
G. B. Perchick and H. N. Jabbour
Cyclooxygenase-2 Overexpression Inhibits Cathepsin D-Mediated Cleavage of Plasminogen to the Potent Antiangiogenic Factor Angiostatin
Endocrinology, December 1, 2003; 144(12): 5322 - 5328.
[Abstract] [Full Text] [PDF]